Evaluation of HLA Matchmaker Compatibility as Predictor of Graft Survival and Presence of Anti-HLA Antibodies

The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation

“…15 However, a similar association was not observed between class I eplet HLA mismatches and overall graft loss. 16 These studies were limited by short follow-up period and analysis restricting to predominantly class I mismatches.…”

“…16-19 Although increasing number of eplet HLA mismatches may increase the chance of developing dn DSA and acute rejection, the immunogenic potential of eplet mismatches may be dependent on the nature and binding capacity of each eplet HLA mismatch. 20,21 …”

HLA molecular epitope mismatching and long-term graft loss in pediatric heart transplant recipients

“…However, recipients with 2 to 4 allele mismatches and Z10 eplet mismatches, representing most of the cohort, experienced substantially reduced graft survival. Although the HLA Matchmaker program has been studied and used for clinical applications in kidney transplantation, 7,8 no prior studies on the outcomes of either adult or pediatric recipients of heart transplants have used this approach. Freedom from graft loss by number of class I HLA allele mismatches stratifying more highly mismatched recipients by number of class I molecular eplet mismatches.…”

Predicting Alloreactivity in Transplantation

“…Nevertheless, the eplet version of HLAMatchmaker provides further discrimination of highly divergent HLA specificities [60]. Although conflicting results were reported with regard to the prognostic information that is provided by HLAMatchmaker on graft outcome ([63–66], reviewed in [67]), it is generally accepted that HLAMatchmaker is a suitable tool to analyze serum antibodies and to identify acceptable mismatches in solid-organ transplantation [67]. However, HLAMatchmaker is inappropriate for HSCT donor selection [62].…”